Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.

Ahmad A TarhiniNi KangSandra J LeeF Stephen HodiGary I CohenOmid HamidLaura F HutchinsJeffrey A SosmanHarriet M KlugerZeynep ErogluHenry B KoonDonald P LawrenceKari L KendraDavid R MinorCarrie B LeeMark R AlbertiniLawrence E FlahertyTeresa M PetrellaHoward StreicherVernon K SondakJohn M Kirkwood

Published in: Journal for immunotherapy of cancer (2022)

Rash and endocrine irAEs were independent prognostic factors of RFS and OS in patients treated with adjuvant ipilimumab. Patients experiencing lower grade irAEs derived the most benefit, but we found no significant evidence supporting a negative impact of high dose corticosteroids and immunosuppressants more commonly used to manage grades 3-4 irAEs.

Keyphrases

prognostic factors
high dose
end stage renal disease
early stage
chronic kidney disease
newly diagnosed
low dose
peritoneal dialysis
stem cell transplantation